Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.
Yuhong Zhou(Sun Yat-sen University), Weiqi Lu(Fudan University Shanghai Cancer Center), Rongkui Luo(Sun Yat-sen University), Yang You(East China University of Science and Technology), Zhengqing Song(Fudan University), Yuqin Ding(Sun Yat-sen University), Wei Li(Xuzhou Medical College), Zhiming Wang(Guangzhou University of Chinese Medicine), Yong Zhang(Lanzhou University), Yi Feng, Chenlu Zhang(Northwestern University), Meiyu Fang(Tianjin University), Hanxing Tong(Sun Yat-sen University), Xi Guo(Zhongshan Hospital), Rongyuan Zhuang(Zhongshan Hospital), Zhengfu Fan(Ministry of Education)
Cited by 1
Related Papers
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer
|Cell Death and Disease|2019|381
Progress in Hydrogels for Skin Wound Repair
|Macromolecular Bioscience|2022|251
The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction
|Frontiers in Endocrinology|2022|222
Structural basis of GPBAR activation and bile acid recognition
|Nature|2020|190